Solid Biosciences Inc. cotiza a 6.71 USD y tiene una capitalización bursátil de $719M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial;…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.38 | $-0.53 | $-0.48 |
| Estimado | $-0.41 | $-0.47 | $-0.52 | $-0.44 |
| Sorpresa | — | +19.1% | -1.9% | -9.1% |
| Métrica | SLDB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -96.8% | -40.4% | -56.4% |
| ROA | -75.0% | -32.0% | -43.0% |
| Current Ratio | 6.14 | 2.84 | +3.30 |
| Debt / Equity | — | 0.28 | — |